Exicure Stock - Thursday technicals and trading picture

Edited by ad hoc news Chart & Technicals Desk. Verified prior to publication on 06/18/2026, 17:40 UTC. Details in the imprint.

Exicure (US30205M1027) remains a very small biotech stock with no new filings or press releases on Thursday, according to the company's investor relations page and recent SEC documents. The market's attention is therefore on the technical picture and the thin trading in the shares.

What recent data show

Exicure has shifted from a formerly Nasdaq-listed biotech into an over-the-counter traded micro-cap, after earlier strategic and financial difficulties that culminated in a delisting and restructuring. This is documented in past SEC filings detailing going-concern risks and reverse stock splits.

The company's investor relations page currently shows no new press releases or SEC filings dated in the last few days, and no fresh clinical or deal updates. That quiet news backdrop leaves the few active market participants to focus mainly on liquidity, spread behavior and chart levels rather than fundamentals in the very short term.

Thursday focus on chart and volatility

On Thursday the Exicure quotation continues to trade on the OTC market with very low volume, which tends to lead to wide bid-ask spreads and sporadic prints rather than a continuous order book, according to recent quote data on finance portals tracking the ticker XCUR. In such an illiquid setting, even small orders can move the last-traded price noticeably.

Given the thin trading, classical technical markers like the 50-day or 200-day moving average are of limited informational value for Exicure, because a single outlier trade can distort short-term averages. Nonetheless, chart services still compute these lines, and they illustrate how far the stock has fallen from historic levels when it was regularly traded on Nasdaq before the delisting.

How Exicure tries to create value

Exicure's historic core was the development of therapeutics using spherical nucleic acid (SNA) technology, with past programs in neurology and immuno-oncology described in earlier company materials. More recently the company has repositioned as a biotech shell exploring strategic alternatives and potential transactions, rather than advancing a broad proprietary clinical pipeline.

Where the stock trades today

The shares of Exicure (US30205M1027) last traded on the US OTC market at around $0.01 on 06/18/2026, 17:30 UTC, based on indicative quote data in US dollars from major financial portals.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.